UA138652U - METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS - Google Patents

Abstract

The method of predicting the development of osteoarthritis includes clinical examination, radiography. Additionally, in the patient's serum determine the polymorphism of genes of methylenetetrahydrofolate reductase (MTHFR C677T), nitric oxide synthase (eNOS T786C), the content of thrombomodulin, cobalamin, transforming growth factor beta 1 (сій-b7-C) and thrombomodulin> 5 ng / ml, cobalamin <300 ng / ml, ΤΦΡ-b1 <14 ng / ml predict the development of osteoarthritis.

Description

The proposed useful model belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in the diagnosis of the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include x-rays, examination of biopsies of the synovial membrane, synovial fluid, and cartilage biopsies (A.N.

Okorokov Diagnosis of diseases of internal organs. - M., 2001. - Vol. 2. - P. 186-196). The disadvantage of these methods is the lack of the possibility of predicting the dynamics of the process in the early subclinical stages, preventing its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The task is solved by the fact that in the method of predicting the development of osteoarthritis, which includes a clinical examination and radiography, according to a useful model, polymorphisms of the genes methylenetetrahydrofolate reductase (MTNEK Сб677Т), nitric oxide synthase (еМО5 1Т786С), the content of thrombomodulin, cobalamin, transforming growth factor beta 1 (TGF-B1). With homozygous carrier 677-TT, 786-SS, levels of thrombomodulin 25 ng/ml, cobalamin "300 ng/ml, TGF-VI1 "14 ng/ml predict the development of osteoarthritis.

Application of the method. During hospitalization, the patient is examined, X-rays are taken, the polymorphism of MTNEK C677tT, eMmo5 T786C genes is determined, the content of thrombomodulin, cobalamin, TGF-B1 is determined by the immunoenzymatic method. With homozygous carriers of 677-HT, 786-SS, levels of thrombomodulin "5 ng/ml, cobalamin "300 ng/ml, TGF-VI "14 ng/ml predict the development of osteoarthritis.

An example of using the method.

Patient P., 64 years old, was hospitalized in the clinic due to pain syndrome of the left hip joint. Examined, X-ray taken. No signs of osteoarthritis were found. The polymorphism of MTNEK C677tT and emoz T786C genes was determined in blood serum. The content of thrombomodulin, cobalamin, TGF-B1 was determined by immunoenzymatic method. Established homozygous carrier 677-

TT and 786-SS, thrombomodulin levels - 13 ng/ml, cobalamin - 225 ng/ml, TGF-B1 - 7.5 ng/ml.

The development of osteoarthritis was diagnosed. After 11 months, X-rays revealed phenomena

Koo) osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Claims (1)

USEFUL MODEL FORMULA The method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, which is distinguished by the fact that in the patient's blood serum polymorphism of the genes methylenetetrahydrofolate reductase (MTNEV C677T), nitric oxide synthase (EMO5 1786С), the content of thrombomodulin, cobalamin, transforming growth factor beta 1 ( TFR-RI) and with homozygous carriers of 677-TT, 786-SS and levels of thrombomodulin "5 ng/ml, cobalamin "300 ng/ml, TFR-RI "14 ng/ml predict the development of osteoarthritis.